TABLE 5.
Antimicrobial susceptibilities of 32 E. coli isolates recovered from the faecal samples of Canada geese residing in 3 counties of North‐Central Oklahoma
| Payne county (n = 11) | Oklahoma county (n = 15) | Tulsa county (n = 6) | Total (n = 32) | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Susceptible n (%) 5% CI |
Intermediate n (%) 5% CI |
Resistant n (%) 5% CI |
Susceptible n (%) 95% CI |
Intermediate n (%) 95% CI |
Resistant n (%) 95% CI |
Susceptible n (%) 95% CI |
Intermediate n (%) 95% CI |
Resistant n (%) 95% CI |
Susceptible n (%) 95% CI |
Intermediate n (%) 95% CI |
Resistant n (%) 95% CI |
|
| Amikacin |
11 (100.0) 73.6–100.0 |
0 (0.0) 0.0–26.5 |
0 (0.0) 0.0–26.5 |
15 (100.0) 77.8–100.0 |
0 (0.0) 0.0–22.2 |
0 (0.0) 0.0–22.2 |
5 (83.3) 41.1–99.1 |
1 (16.7) 0.86–58.9 |
0 (0.0) 0.0–41.1 |
31 (96.9) 83.4–99.8 |
1 (3.1) 0.17–16.6 |
0 (0.0) 0.0–10.5 |
| Amoxicillin‐clavulanate |
4 (36.4) 13.5–66.7 |
6 (54.6) 26.5–80.0 |
1 (9.1) 0.47–40.4 |
10 (66.7) 39.7–85.8 |
5 (33.3) 14.2–60.3 |
0 (0.0) 0.0–22.2 |
4 (66.7) 27.1–93.7 |
2 (33.3) 6.3–72.9 |
0 (0.0) 0.0–41.1 |
18 (56.3) 39.0–72.2 |
13 (40.6) 24.7–58.0 |
1 (3.1) 0.17–16.6 |
| Ampicillin |
8 (72.7) 40.5–92.1 |
1 (9.1) 0.47–40.4 |
2 (18.2) 33.4–50.0 |
10 (66.7) 39.7–85.8 |
5 (33.3) 14.2–60.3 |
0 (0.0) 0.0–22.2 |
6 (100.0) 58.9–100.0 |
0 (0.0) 0.0–41.1 |
0 (0.0) 0.0–41.1 |
24 (75.0) 57.7–87.8 |
6 (18.8) 8.5–35.8 |
2 (6.3) 1.1–20.0 |
| Azithromycin |
5 (45.5) 20.0–73.5 |
0 (0.0) 0.0–26.5 |
6 (54.6) 26.5–80.0 |
9 (60.0) 33.2–80.9 |
0 (0.0) 0.0–22.2 |
6 (40.0) 19.1–66.8 |
2 (33.3) 6.3–72.9 |
0 (0.0) 0.0–41.1 |
4 (66.7) 27.1–93.7 |
16 (50.0) 32.6–67.4 |
0 (0.0) 0.0–10.5 |
16 (50.0) 32.6–67.4 |
| Cefoxitin |
10 (90.9) 59.6–99.5 |
1 (9.1) 0.47–40.4 |
0 (0.0) 0.0–26.5 |
15 (100.0) 77.8–100.0 |
0 (0.0) 0.0–22.2 |
0 (0.0) 0.0–22.2 |
6 (100.0) 58.9–100.0 |
0 (0.0) 0.0–41.1 |
0 (0.0) 0.0–41.1 |
31 (96.9) 83.4–99.8 |
1 (3.1) 0.17–16.6 |
0 (0.0) 0.0–10.5 |
| Chloramphenicol |
9 (81.8) 50.0–96.7 |
1 (9.1) 0.47–40.4 |
1 (9.1) 0.47–40.4 |
15 (100.0) 77.8–100.0 |
0 (0.0) 0.0–22.2 |
0 (0.0) 0.0–22.2 |
6 (100.0) 58.9–100.0 |
0 (0.0) 0.0–41.1 |
0 (0.0) 0.0–41.1 |
30 (93.8) 80.0–98.9 |
1 (3.1) 0.17–16.6 |
1 (3.1) 0.17–16.6 |
| Ciprofloxacin |
11 (100.0) 73.6–100.0 |
0 (0.0) 0.0–26.5 |
0 (0.0) 0.0–26.5 |
15 (100.0) 77.8–100.0 |
0 (0.0) 0.0–22.2 |
0 (0.0) 0.0–22.2 |
5 (83.3) 41.1–99.1 |
1 (16.7) 0.86–58.9 |
0 (0.0) 0.0–41.1 |
31 (96.9) 83.4–99.8 |
1 (3.1) 0.17–16.6 |
0 (0.0) 0.0–10.5 |
| Gentamicin |
11 (100.0) 73.6–100.0 |
0 (0.0) 0.0–26.5 |
0 (0.0) 0.0–26.5 |
15 (100.0) 77.8–100.0 |
0 (0.0) 0.0–22.2 |
0 (0.0) 0.0–22.2 |
6 (100.0) 58.9–100.0 |
0 (0.0) 0.0–41.1 |
0 (0.0) 0.0–41.1 |
32 (100.0) 89.5–100.0 |
0 (0.0) 0.0–10.5 |
0 (0.0) 0.0–10.5 |
| Kanamycin |
2 (18.2) 33.4–50.0 |
9 (81.8) 50.0–96.7 |
0 (0.0) 0.0–26.5 |
3 (20.0) 5.7–46.6 |
12 (80.0) 53.4–94.3 |
0 (0.0) 0.0–22.2 |
0 (0.0) 0.0–41.1 |
5 (83.3) 41.1–99.1 |
1 (16.7) 0.86–58.9 |
5 (15.6) 6.4–32.6 |
26 (81.3) 64.2–91.5 |
1 (3.1) 0.17–16.6 |
| Meropenem |
11 (100.0) 73.6–100.0 |
0 (0.0) 0.0–26.5 |
0 (0.0) 0.0–26.5 |
15 (100.0) 77.8–100.0 |
0 (0.0) 0.0–22.2 |
0 (0.0) 0.0–22.2 |
6 (100.0) 58.9–100.0 |
0 (0.0) 0.0–41.1 |
0 (0.0) 0.0–41.1 |
32 (100.0) 89.5–100.0 |
0 (0.0) 0.0–10.5 |
0 (0.0) 0.0–10.5 |
| Nalidixic acid |
10 (90.9) 59.6–99.5 |
1 (9.1) 0.47–40.4 |
0 (0.0) 0.0–26.5 |
14 (93.3) 69.8–99.6 |
1 (6.7) 0.35–30.2 |
0 (0.0) 0.0–22.2 |
5 (83.3) 41.1–99.1 |
1 (16.7) 0.86–58.9 |
0 (0.0) 0.0–41.1 |
29 (90.6) 75.3–97.4 |
3 (9.4) 2.6–24.7 |
0 (0.0) 0.0–10.5 |
| Tetracycline |
10 (90.9) 59.6–99.5 |
0 (0.0) 0.0–26.5 |
1 (9.1) 0.47–40.4 |
12 (80.0) 53.4–94.3 |
1 (6.7) 0.35–30.2 |
2 (13.3) 2.4–39.7 |
6 (100.0) 58.9–100.0 |
0 (0.0) 0.0–41.1 |
0 (0.0) 0.0–41.1 |
28 (87.5) 71.9–95.6 |
1 (3.1) 0.17–16.6 |
3 (9.4) 2.6–24.7 |
| Trimethoprim‐sulphamethoxazole |
11 (100.0) 73.6–100.0 |
0 (0.0) 0.0–26.5 |
0 (0.0) 0.0–26.5 |
15 (100.0) 77.8–100.0 |
0 (0.0) 0.0–22.2 |
0 (0.0) 0.0–22.2 |
6 (100.0) 58.9–100.0 |
0 (0.0) 0.0–41.1 |
0 (0.0) 0.0–41.1 |
32 (100.0) 89.5–100.0 |
0 (0.0) 0.0–10.5 |
0 (0.0) 0.0–10.5 |